Held by 2 specialist biotech funds
Eventide's $32.8M entry into TRVI signals conviction in the company's lead asset, omaveloxolone, a Nrf2 activator in Phase 3 for friedreich's ataxia (FA)—a rare, progressive neurodegenerative disease with limited treatment options and ~5,000 US patients. The initiation likely reflects anticipation of near-term catalysts, including potential FDA decision on the Phase 3 MOTOR trial readout expected in late 2024/early 2025, which could unlock label approval and commercial opportunity for an underserved indication.